SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation 2007; 116: 1313.
  • 2
    White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 23945.
  • 3
    Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 4727.
  • 4
    Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006; 97: 53843.
  • 5
    Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program 2008: 25965.
  • 6
    Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000; 85: 56872.
  • 7
    Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA, Jr. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008; 24: 8797.
  • 8
    Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001; 22: 19549.
  • 9
    Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009; 54: 12809.
  • 10
    Saitoh M, Kaku S, Funatsu T, Koshio H, Ishihara T, Hirayama F, Kawasaki T, Sasamata M. Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models. Blood 2007; 110: Abstract 3155.
  • 11
    Iwatsuki Y, Shigenaga T, Moritani Y, Suzuki M, Ishihara T, Hirayama F, Kawasaki T. Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. Eur J Clin Pharmacol 2011; 673: 4955.
  • 12
    Kaku S, Suzuki K, Funatsu T, Saitoh M, Koshio H, Ishihara T, Hirayama F, Kawasaki T. Effects of direct factor Xa inhibitor, YM150, on clot formation and clot lysis in vitro compared with other anticoagulants. Blood 2007; 110: Abstract 3153.
  • 13
    Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29: 15565.
  • 14
    Shiraga T, Yajima K, Hashimoto T, Iwatsubo T, Miyashita A, Usui T. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine. Drug Metab Dispos 2012; 40: 27682.
  • 15
    Hashimoto T, Iwai M, Li Q, Shimaya J, Nemoto H, Ohzone Y, Iwatsubo T, Usui T. Drug transporters involved in the pharmacokinetics of YM150, a novel factor Xa inhibitor in humans. Drug Metab Rev 2011; 32: 3089. Abstract 93.
  • 16
    Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 71421.
  • 17
    Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L; ONYX-2 STUDY GROUP. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 16605.
  • 18
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 286778.
  • 19
    Jungbauer L, Dobias C, Stollberger C, Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost 2010; 8: 206970.
  • 20
    Bristol-Myers Squibb. Coumadin Prescribing Information. 2010 Available at http://packageinserts.bms.com/pi/pi_coumadin.pdf (last accessed 2011 January).
  • 21
    European Medicines Agency. Xarelto EPAR Product Information, EMEA/H/C/000944 -II/0007. 2011 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (last accessed 28 June 2011).
  • 22
    Food and Drug Administration. Pradaxa. 2011 Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s004lbl.pdf (last accessed 27 June 2011).
  • 23
    Food and Drug Administration. Guidance for Industry. Drug interaction studies – study design, data analysis and implications for dosing and labelling. 2006.
  • 24
    Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 81950.
  • 25
    Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 50921.
  • 26
    Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35: 14007.
  • 27
    Groenendaal D, Heeringa M, Kadokura T, Verheggen F, Strabach G, Heinzerling H. YM150, an oral direct inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic/pharmacodynamic profile after single and multiple dosing: results from three studies. Blood 2010; 116: 3323.
  • 28
    Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 10827.
  • 29
    Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010; 88: 37582.
  • 30
    Heeringa M, Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Mol R, Eltink C, Heinzerling H. The pharmacokinetics of YM150, an oral direct factor Xa inhibitor, are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-gp. J Thromb Haemost 2011; 9: (Suppl 2): 35960. Abstract P-TU-163.
  • 31
    European Medicines Agency. Pradaxa EPAR. Product Information. EMEA/H/C/000829 -II/0011. 2009. Updated 8th June 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (last accessed 14 July 2011).
  • 32
    European Medicines Agency. Eliquis EPAR Product Information. EMEA/H/C/002148. 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (last accessed 27 June 2011).
  • 33
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 63541.
  • 34
    Ezekowitz MD. EXPLORE-Xa, A Phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa). Available at http://assets.cardiosource.com/ezekowitz_explore1.ppt (last accessed 1 July 2011).
  • 35
    Masumoto H, Yoshigae Y, Watanabe K, Takakusa H, Okazaki O, Izumi T. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. AAPS J 2010; 12: W4308.
  • 36
    Sanofi-Aventis. Prescribing information Multaq (US-label). 2011 Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022425s010lbl.pdf (last accessed 1 July 2011).
  • 37
    Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156: 31929.
  • 38
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 111625.
  • 39
    Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64: 95667.